ELCC 2018: Patient-Reported Outcomes With Durvalumab From PACIFIC Trial
Posted: Tuesday, May 1, 2018
Based on a post hoc analysis of the time to deterioration of symptoms with durvalumab therapy from the PACIFIC trial, patients with stage III locally advanced, unresectable non–small cell lung cancer (NSCLC) experienced a delay in several patient-reported outcomes that were not observed in the prespecified analysis. Rina Hui, MBBS, FRACP, PhD, of Westmead Clinical School of Australia, and her colleagues suggest that confirmation of worsening of symptoms associated with durvalumab therapy “may provide a more precise picture of deterioration than one time point alone.” These findings were presented by Dr. Hui at the European Lung Cancer Conference (ELCC) 2018 in Geneva (Abstract 233O).
The investigators explored the impact of 12 months of durvalumab on disease symptoms in patients from the PACIFIC trial. In the prespecified analysis, there appeared to be no difference between treatment arms in the time to deterioration (aside from pain, which favored duravalumab). However, in the post hoc analysis, patients treated with durvalumab experienced “notable delays” in deterioration of overall pain, chest pain, arm/shoulder pain, nausea/vomiting, insomnia, and hemoptysis.
The randomized, double-blind, placebo-controlled PACIFIC trial included 713 patients with unresectable stage III NSCLC. Patients had completed concurrent platinum-based chemotherapy and radiation therapy within 42 days prior to receiving durvalumab. The primary study analysis reported a significant improvement in progression-free survival with durvalumab over placebo in this patient population (16.8 vs. 5.6 months).
